Neumora Therapeutics, Inc. Common Stock
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
0.00 |
0.00 |
3.89 |
21.01 |
91.88 |
260.48 |
| Przychód Δ r/r |
0.00% |
0.00% |
inf% |
440.82% |
337.20% |
183.50% |
| Przychód (min) |
0.00 |
0.00 |
3.89 |
21.01 |
91.88 |
260.48 |
| Przychód (max) |
0.00 |
0.00 |
3.89 |
21.01 |
91.88 |
260.48 |
| EBITDA (średnia) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| EBIT (średnia) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| EBIT % |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| Zysk netto (średni) |
-245.58 |
-225.62 |
-214.50 |
-210.46 |
-134.94 |
-38.78 |
| Zysk netto % |
-inf% |
-inf% |
-5520.14% |
-1001.49% |
-146.87% |
-14.89% |
| EPS (średnia) |
-1.58 |
-1.42 |
-0.99 |
-0.95 |
-0.85 |
-0.24 |
| Liczba analityków (Przychody) |
0 |
0 |
8 |
7 |
4 |
3 |
| Liczba analityków (EPS) |
6 |
6 |
7 |
6 |
3 |
4 |
| symbol |
NMRA |
NMRA |
NMRA |
NMRA |
NMRA |
NMRA |